HESKA CORP Form 10-O November 07, 2018

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE

* SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2018

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE $^{\rm O}$ SECURITIES EXCHANGE ACT OF 1934

For the transition period from _ to _

Commission file number: 0-22427

HESKA CORPORATION

(Exact name of registrant as specified in its charter) 77-0192527 Delaware (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification Number)

3760 Rocky Mountain Avenue

Loveland, Colorado 80538 (Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code:

(970) 493-7272

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer,"

"accelerated filer", "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer o Accelerated filer x

Non-accelerated filer o Smaller Reporting Company "

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes o No x

7,589,249 shares of the Registrant's Public Common Stock, \$.01 par value, were outstanding at November 6, 2018.

TABLE OF CONTENTS

		Page
PART I -	FINANCIAL INFORMATION	
Item 1.	<u>Financial Statements</u>	<u>1</u>
	Condensed Consolidated Balance Sheets	<u>1</u>
	Condensed Consolidated Statements of Income	<u>2</u>
	Condensed Consolidated Statements of Comprehensive Income	<u>3</u>
	Condensed Consolidated Statements of Stockholders' Equity	<u>4</u>
	Condensed Consolidated Statements of Cash Flows	<u>5</u>
	Notes to Condensed Consolidated Financial Statements	<u>6</u>
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	<u>28</u>
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	<u>38</u>
Item 4.	Controls and Procedures	<u>38</u>
PART II	- OTHER INFORMATION	
Item 1.	<u>Legal Proceedings</u>	<u>38</u>
Item 1A.	. Risk Factors	<u>38</u>
Item 6.	<u>Exhibits</u>	<u>39</u>
	<u>Signatures</u>	<u>40</u>

HESKA, ALLERCEPT, HEMATRUE, SOLO STEP, Element DC, Element HT5, Element POC, Element i, Element COAG and Element DC5x are registered trademarks and SonoSlate is a trademark of Heska Corporation. DRI-CHEM is a registered trademark of FUJIFILM Corporation. TRI-HEART is a registered trademark of Intervet Inc., d/b/a Merck Animal Health, formerly known as Schering-Plough Animal Health Corporation ("Merck Animal Health"), which is a unit of Merck & Co., Inc., in the United States and is a registered trademark of Heska Corporation in other countries. This quarterly report on Form 10-Q also refers to trademarks and trade names of other organizations.

- i-

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

HESKA CORPORATION AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except share and per share amounts)

ASSETS Current assets:	September 30, 2018 (unaudited)	December 31, 2017
Current assets: Cash and cash equivalents Accounts receivable, net of allowance for doubtful accounts of \$234 and \$215, respectively Due from – related parties Inventories, net Lease receivable, current, net of allowance for doubtful accounts of \$36 and \$0, respectively Contract acquisition costs, current Other current assets Total current assets	\$9,236 13,647 — 27,639 2,777 840 3,904 58,043	\$9,659 15,710 1 32,596 2,069 30 3,066 63,131
Property and equipment, net Goodwill and intangible assets, net Deferred tax asset, net Lease receivable, non-current Investments in unconsolidated affiliates Contract acquisition costs, non-current Other non-current assets Total assets	16,284 28,349 13,851 11,521 8,089 1,623 6,360 \$144,120	17,331 28,645 11,877 9,615 — 3 5,185 \$135,787
LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable Due to – related parties Accrued liabilities Current portion of deferred revenue Line of credit and other short-term borrowings Total current liabilities	\$4,545 280 10,518 2,766 6,019 24,128	\$9,489 1,828 4,417 3,992 6,000 25,726
Deferred revenue, net of current portion, and other Total liabilities Commitments and contingencies (Note 13)	8,391 32,519	9,621 35,347
Stockholders' equity: Preferred stock, \$.01 par value, 2,500,000 shares authorized, none issued or outstanding Common stock, \$.01 par value, 10,250,000 and 10,000,000 shares authorized, respectively, none issued or outstanding	 76	

Public common stock, \$.01 par value, 10,250,000 and 10,000,000 shares authorized,

7,552,596 and 7,302,954 shares issued and outstanding, respectively

Additional paid-in capital	249,755 243,598
Accumulated other comprehensive income	216 232
Accumulated deficit	(138,446) (143,463)
Total stockholders' equity	111,601 100,440
Total liabilities and stockholders' equity	\$144,120 \$135,787

See accompanying notes to condensed consolidated financial statements.

-1-

HESKA CORPORATION AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(in thousands, except per share amounts) (unaudited)

(unaudicu)	Three Mo Ended Se 30, 2018		Nine Mor Ended Se 30, 2018	
Revenue:	2010	2017	2010	2017
Core companion animal health	\$27,190	\$25,578	\$80,652	\$75,453
Other vaccines, pharmaceuticals and products	3,765	4,758	12,729	17,847
Total revenue, net	30,955	30,336	93,381	93,300
Cost of revenue	16,161	16,783	52,215	51,609
Gross profit	14,794	13,553	41,166	41,691
Operating expenses:				
Selling and marketing	6,215	5,815	18,299	17,908
Research and development	935	601	2,165	1,576
General and administrative	11,239	3,359	20,223	11,081
Total operating expenses	18,389	9,775	40,687	30,565
Operating (loss) income	(3,595)	3,778	479	11,126
Interest and other (income) expense, net			37	(186)
(Loss) income before income taxes	(3,545)	3,784	442	11,312
Income tax expense (benefit):				
Current income tax expense	27	8	56	25
Deferred income tax (benefit) expense	(1,902)	693	(1,997)	762
Total income tax (benefit) expense	(1,875)	701	(1,941)	787
Net (loss) income	(1,670)	3.083	2,383	10,525
Net loss attributable to non-controlling interest	(1,070)			(498)
Net (loss) income attributable to Heska Corporation	\$(1,670)	\$3.083	\$2,383	\$11,023
The (1000) meonic dianodadore to Heona Corporation	Ψ(1,070)	Ψ3,003	Ψ2,505	Ψ11,023
Basic (loss) earnings per share attributable to Heska Corporation	\$(0.23)	\$0.43	\$0.33	\$1.58
Diluted (loss) earnings per share attributable to Heska Corporation	\$(0.23)		\$0.30	\$1.45
1	, ,			
Weighted average outstanding shares used to compute basic (loss) earnings	7,289	7,139	7,194	6,985
per share attributable to Heska Corporation	1,409	1,137	/,1 <i>7</i> 11	0,903
Weighted average outstanding shares used to compute diluted (loss)	7,289	7,668	7,820	7,580
earnings per share attributable to Heska Corporation	.,_0,	,,000	.,020	.,500

See accompanying notes to condensed consolidated financial statements.

HESKA CORPORATION AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (in thousands) (unaudited)

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2018	2017	2018	2017
Net (loss) income Other comprehensive income (loss):	\$(1,670)	\$3,083	\$2,383	\$10,525
Foreign currency translation	15	(45)	(16)	125
Comprehensive (loss) income	(1,655)	3,038	2,367	10,650
Comprehensive loss attributable to non-controlling interest Comprehensive (loss) income attributable to Heska Corporation	 \$(1,655)	- \$3,038	 \$2,367	(498) \$11,148

See accompanying notes to condensed consolidated financial statements.

-3-

Accumulated

HESKA CORPORATION AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (in thousands) (unaudited)

Three Months Ended September 30, 2017 and 2018	Common Stock SharesAmou	Additiona Paid-in Capital nt		iv A ccumulated Deficit	Total l Stockholde Equity	rs'
Balances, June 30, 2017 Net income	7,196 \$ 72 — —	\$241,575 —	\$ 267 —	\$(145,339) 3,083	\$ 96,575 3,083	
Issuance of common stock, net of shares withheld for employee taxes	48 —	716	_	_	716	
Stock-based compensation Distribution for Heska Imaging minority interest Other comprehensive loss Balances, September 30, 2017	 	707 — — \$ 242,998			707 (9 (45 \$ 101,027)
Balances, June 30, 2018 Net loss Issuance of common stock, net of shares withheld	7,498 \$ 75	\$246,422 — 1,927	\$ 201 —	\$(136,776))
for employee taxes Stock-based compensation Other comprehensive income Balances, September 30, 2018	 7,553 \$ 76	1,406 — \$249,755	 15 \$ 216	 \$(138,446)	1,406 15 \$ 111,601	
•						
	Common Stock	Additiona Paid-in Capital		d siv a ccumulated Deficit	Total I Stockholde Equity	rs'
Nine Months Ended September 30, 2017 and 2018 Balances, December 31, 2016 Net income	Stock	Paid-in	l Other Comprehens	iv A ccumulated	d Stockholde Equity	rs'
Nine Months Ended September 30, 2017 and 2018 Balances, December 31, 2016 Net income Issuance of common stock, net of shares withheld	Stock SharesAmou 7,026 \$ 70	Paid-in Capital nt	Other Comprehens Income	siv A ccumulated Deficit \$(151,827)	d Stockholde Equity \$86,975	rs'
Nine Months Ended September 30, 2017 and 2018 Balances, December 31, 2016 Net income	Stock 3 SharesAmou 7,026 \$ 70 — —	Paid-in Capital nt \$238,635	Other Comprehens Income \$ 97	Deficit \$ (151,827) 10,525	Stockholde Equity \$ 86,975 10,525 1,427 2,093 845 (963 125	rs'

Issuance of common stock, net of shares withheld

for employee taxes

 Stock-based compensation
 —
 3,774
 —
 3,774

 Other comprehensive loss
 —
 —
 (16
)
 —
 (16
)

 Balances, September 30, 2018
 7,553
 76
 \$249,755
 \$ 216
 \$(138,446)
 \$ 111,601

See accompanying notes to condensed consolidated financial statements.

-4-

HESKA CORPORATION AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands) (unaudited)

> Nine Months Ended September 30, 2018 2017

CASH FLOWS FROM OPERATING ACTIVITIES: Net income